RYE
BROOK, N.Y., May 22, 2024
/PRNewswire/ -- Today, The Leukemia & Lymphoma Society's (LLS)
Equity in Access Research Program announced the opening of its
application process for the 2025 funding cycle. Now through
September 12, 2024, researchers are
invited to submit Letters of Intent for studies that align with the
topic of "Building Evidence for Effective Interventions to
Increase Therapeutic Cancer Clinical Trial Accrual: Promoting
Access for Patients from Underrepresented Groups." LLS's Equity
in Access Research Program will review submissions to allocate up
to $2.5 million per funded study,
with awards to begin next summer.
"For LLS, a key part of advancing health equity is a commitment
to reducing and ultimately eliminating health disparities that
impact patients with and survivors of a blood cancer," said
Eric Cooks, Ph.D., Senior Program
Director of LLS's Equity in Access Research Program. "This program
is designed to generate evidence that will guide changes in
healthcare policy and practice to ensure that all individuals
affected by blood cancer can access and utilize the treatment,
care, and resources necessary to optimize their quality of life and
outcomes, throughout their journey from diagnosis to
survivorship."
LLS's Equity in Access Research Program Key Dates &
Deadlines:
- May 22, 2024: Application
period begins
- June 18, 2024 (12:00 p.m. ET): Webinar for prospective
applicants (register here)
- September 12, 2024
(3:00 p.m. ET): Deadline to
submit Letters of Intent
- November 1, 2024: LLS
notifies applicants whether they are invited to submit a full
proposal
- January 30, 2025 (3:00 p.m. ET): Deadline for invited
applicants to submit full proposals and associated documents
- April/May 2025:
Notification of awards
- July 1, 2025: Grant start
date
To learn more about LLS's Equity in Access Research
Program, including how to apply, study criteria, key dates and
deadlines, award amounts, and more, visit
https://www.lls.org/research/equity-access-research-grants.
Since its launch in 2022, LLS's Equity in Access Research
Program has awarded more than $5
million in funding to health services researchers across the
US. The work funded through the program is making an impact and
gaining recognition – earlier this year, an article co-authored by
Dr. Stacie Dusetzina, a health
policy researcher at Vanderbilt
University, and Dr. Lauren
Nicholas, a health economist at the University of Colorado Anschutz, titled
"Comparing Medicare plan selection among beneficiaries with and
without a history of cancer," was selected as an "Editor's
Choice" article by Health Affairs Scholar.
LLS proudly and gratefully acknowledges the leadership support
of Royalty Pharma and AstraZeneca for their support of the Equity
in Access Research Program and other initiatives focused on
reducing healthcare disparities in blood cancer care and
treatment.
This year, LLS's Equity in Access Research Program team will be
onsite in Chicago at the 2024
ASCO Annual Meeting from June 1 – 3.
To learn more about the program and the current Request for
Proposals, please stop by booth #10005 to speak with an LLS
representative.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the global
leader in the fight against blood cancer. The LLS mission: Cure
leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the
quality of life of patients and their families. LLS funds
lifesaving blood cancer research around the world, provides free
information and support services, and is the voice for all blood
cancer patients seeking access to quality, affordable, coordinated
care.
Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout
the United States and Canada. To learn more, visit
www.LLS.org. Patients should contact the Information
Resource Center at (800) 955-4572, Monday through Friday,
9 a.m. to 9 p.m. ET.
For additional information,
visit lls.org/lls-newsnetwork. Follow us on
Facebook, Twitter, and Instagram.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-leukemia--lymphoma-society-is-accepting-applications-for-up-to-2-5-million-in-funding-through-its-equity-in-access-research-program-302152898.html
SOURCE The Leukemia & Lymphoma Society (LLS)